Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma

Inclusion Criteria

• •Measurable monoclonal protein in the serum (for immunoglobin \[Ig\]G or IgM, \>= 1.0 g/dL using serum protein electrophoresis \[SPEP\]/immunofixation electrophoresis \[IFE\]; for IgA, an SPEP/IFE confirming the presence of a monoclonal IgA band plus a quantitative IgA level of \>= 750 mg/dL) OR measurable urine Bence Jones paraprotein (\>= 500mg/24hrs) OR a measurable serum free light chain (FLC), defined as an involved FLC level of \>10 mg/dl, and a serum FLC ratio that is abnormal
• •Neutrophil count \>= 1,500
• •Platelet count \>= 100,000
• •Hemoglobin \>= 9mg/dL
• •Alanine aminotransferase (ALT) =\< institutional upper limit of normal (IULN)
• •Aspartate aminotransferase (AST) =\< IULN
• •Total bilirubin =\< IULN
• •Alkaline phosphatase =\< IULN
• •Any ethnic group
• •Prior therapy is allowed if \>= 4 weeks prior to registration
• •Life expectancy of at least 6 months
• •Ability to understand and the willingness to sign a written informed consent document
• •Willingness to comply with oral home treatment and visit schedule
• •Patients with reproductive capacity must be willing to use adequate contraception (barrier contraception, birth control pills, or other highly effective hormonal agents) or abstain from sexual activity for the duration of the study and 30 days beyond the end of therapy